Aspire Biopharma Reports Q3 2025 Business Developments

Aspire Biopharma Holdings, Inc. has announced several key developments for the third quarter ended September 30, 2025. The company expanded its scientific team with Dr. Mark J. Jaroszeski, aimed at advancing its sublingual delivery technology. A notable achievement was the submission of a Pre-IND meeting request to the FDA for its high-dose sublingual aspirin formulation, targeting acute myocardial infarction. Additionally, Aspire took part in the CPHI Frankfurt trade show, resulting in potential licensing opportunities.

The company filed an omnibus patent application to protect its sublingual drug delivery technology. This advancement emphasizes enhancing the pharmacokinetic performance of active pharmaceutical ingredients. Aspire also focused on marketing its BUZZ BOMB™ caffeine product, increasing production capacity through a partnership with SupraNaturals, and reported positive bioavailability study results.

Operational highlights include appointing Kraig Higginson as interim CEO and the successful launch of BUZZ BOMB™ via e-commerce. Looking ahead, Aspire anticipates significant milestones, including a New Drug Application submission in 2026 and new clinical studies.